BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

It may cause dynamic obstruction to LV outflow and LV filling ... In the form of asymmetrical septal hypertrophy known as idiopathic hypertrophic subaortic stenosis, the proximal septal ...

KMC Hospital in Mangaluru successfully treats Rev Fr Wolfgang Leonhard, a German priest, diagnosed with hypertrophic obstructive cardiomyopathy and complete heart block. The cardiology team implanted ...

Hypertrophic cardiomyopathy (HCM ... This paper presents a case study of a 53-year-old female with a dynamic and obstructive form of HCM. The study includes a case presentation, clinical findings ...

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...

Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...

Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), ...

In a remarkable display of expertise and advanced cardiac care, KMC Hospital, Dr B R Ambedkar Circle successfully treated Fr Wolfgang Leonhard, a 65-year-old German national, who was rushed to the ...